Every October, pink ribbons appear on coffee cups, sports jerseys, and social media profiles. Awareness campaigns remind us that breast cancer touches nearly every Canadian family. What they rarely do is tell us what the science says right now: what's changed, what's been misunderstood, and what questions women should be asking their doctors in 2026.
The Numbers That Matter in Canada
Breast cancer is the most commonly diagnosed cancer among Canadian women. The Canadian Cancer Society estimates that 1 in 8 women in Canada will develop breast cancer in their lifetime, which equates to approximately 78 new diagnoses every single day. It is the second leading cause of cancer-related death in Canadian women, behind lung cancer.
The most important counterbalance to those numbers: when caught early, the five-year survival rate for localized breast cancer exceeds 98%.
What Changed at ASCO 2026: The Genomic Testing Revolution
One of the most significant shifts in breast cancer care involves who actually needs chemotherapy , and new data presented at the 2026 ASCO Annual Meeting suggests the answer is far fewer women than previously thought.
Researchers used a genomic test called Prosigna, which analyzes the biology of a tumor to estimate recurrence likelihood, to guide treatment decisions. The study found that nearly 70% of patients who were considered clinically high risk actually had a low genomic risk and did just as well with hormone therapy alone.
Until now, genomic tests have primarily helped identify lower-risk patients who may not need chemotherapy. The OPTIMA trial is considered potentially practice-changing because it further advances personalized treatment, helping identify which patients are likely to benefit from chemotherapy and which may be spared its short- and long-term side effects. The findings also provided important evidence for premenopausal women aged 40 and older receiving ovarian function suppression, a group in which genomic testing has historically been less established.
The practical implication: if you or someone you love receives a breast cancer diagnosis and is told chemotherapy is recommended, asking about genomic testing specifically whether a Prosigna or OncotypeDX score has been obtained is now one of the most important questions a patient can ask.
GLP-1 Medications and Breast Cancer Risk: What the ASCO Data Shows
One of the most talked-about findings at ASCO 2026 had nothing to do with chemotherapy. Five real-world studies examined whether GLP-1 receptor agonists, the class of medications that includes semaglutide (Ozempic/Wegovy), might influence breast cancer risk and progression.
New retrospective data presented at the 2026 ASCO Annual Meeting suggests that GLP-1 receptor agonists may significantly reduce the incidence of breast cancer. Researchers analyzed health records from 111,646 women between the ages of 45 and 80 with a BMI of 25 or higher, comparing 15,264 women with documented GLP-1 prescriptions to a control group of 96,382 women. The full analysis showed 35.1% lower odds of breast cancer, while the matched cohort demonstrated a 30.5% lower incidence.
The findings on cancer progression were equally striking. For breast cancer specifically, people who took GLP-1s were 45% less likely to develop stage IV cancer than people who did not take these medications.
For patients with hormone receptor-positive, HER2-negative metastatic breast cancer, preliminary data indicate that the addition of GLP-1 receptor agonists to combination endocrine therapy and CDK4/6 inhibitors is associated with a 30% reduction in mortality risk.
Critical context: This observational study does not prove that GLP-1s directly prevent breast cancer. More research is needed before GLP-1s can be considered a cancer prevention or treatment strategy. What it does do is add meaningful momentum to the hypothesis that metabolic health and breast cancer risk are deeply connected — and that interventions targeting metabolic dysfunction may carry cancer-protective benefits beyond weight loss alone.
The HRT and Breast Cancer Conversation are Being Rewritten
Few topics generate more anxiety among women in perimenopause and menopause than hormone replacement therapy and breast cancer. The fear that HRT causes breast cancer has driven millions of women away from treatments that might protect their hearts, bones, and cognitive function. A fear rooted in a single study that has since been substantially revised.
The 2002 Women's Health Initiative study reported a small increased risk of breast cancer with combined estrogen-progestogen HRT. What followed was a dramatic decline in HRT prescribing and a significant increase in untreated menopausal symptoms and cardiovascular disease in postmenopausal women.
Twenty years of follow-up research has clarified the picture considerably. The type of hormone matters enormously: synthetic progestogens carry different risk profiles than body-identical progesterone. The route of delivery matters: transdermal (patch or gel) estrogen carries substantially lower clotting and potentially lower breast cancer risk than oral estrogen. And timing matters most of all: HRT initiated within ten years of menopause onset carries a very different risk-benefit profile than HRT started in later years.
Treatments are becoming increasingly personalized in breast cancer care, and the same personalization is now being applied to the HRT conversation. For women with a history of breast cancer, the calculus is different and requires individualized discussion with an oncologist. For healthy women navigating perimenopause and menopause, the updated evidence suggests that blanket avoidance of HRT based on 2002 data is not supported by the current science.
Screening: What Canadian Women Should Know
The Canadian Task Force on Preventive Health Care recommends routine mammography for women aged 50–74 every two to three years. For women aged 40–49, the recommendation is to discuss individual risk with a physician. For women with a family history of breast cancer, BRCA1/2 mutations, or dense breast tissue, earlier or more frequent screening is generally recommended.
Dense breast tissue deserves special attention. Approximately 40–50% of women have dense breast tissue — which makes tumors harder to detect on standard mammography and is itself an independent risk factor for breast cancer. Dense breast tissue must now be disclosed to patients in several Canadian provinces following advocacy efforts, but what to do with that information varies by province and by physician.
If you have been told you have dense breast tissue, asking about supplemental screening options — including ultrasound or MRI — is a reasonable and well-supported conversation to have with your doctor.
Emerging Treatments
Several key advances are reshaping treatment in 2026. In triple-negative breast cancer, a subtype that is particularly difficult to treat because it lacks several common treatment targets, new studies presented at ASCO offered encouraging news, including antibody-drug conjugates that deliver cancer-fighting drugs directly to tumor cells while limiting damage to healthy tissues.
Five Questions Worth Asking Your Doctor This October
- What is my personal lifetime risk of breast cancer, based on my family history and other factors?
- Do I have dense breast tissue — and if so, what supplemental screening options are available to me?
- If I receive a breast cancer diagnosis, will genomic testing be used to guide whether I need chemotherapy?
- What is the current evidence on HRT and breast cancer risk specifically for my situation?
- What modifiable factors — weight, metabolic health, gut health, alcohol intake — can I address to meaningfully reduce my risk?
References: Canadian Cancer Society Statistics 2026; McDonald E, et al. GLP-1 agonists and breast cancer incidence, JCO Oncol Pract, June 2026. [ASCO Abstract 10506]; Orland MD, et al. GLP-1s and cancer progression, ASCO 2026 Abstract 3143; OPTIMA trial, Prosigna genomic testing, ASCO 2026; NAMS 2022 updated HRT position statement; Canadian Task Force on Preventive Health Care mammography guidelines
